Welcome to LookChem.com Sign In|Join Free

CAS

  • or
ethyl 4-(N'-hydroxycarbamimidoyl)benzoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

40069-10-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 40069-10-1 Structure
  • Basic information

    1. Product Name: ethyl 4-(N'-hydroxycarbamimidoyl)benzoate
    2. Synonyms:
    3. CAS NO:40069-10-1
    4. Molecular Formula:
    5. Molecular Weight: 208.217
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 40069-10-1.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: ethyl 4-(N'-hydroxycarbamimidoyl)benzoate(CAS DataBase Reference)
    10. NIST Chemistry Reference: ethyl 4-(N'-hydroxycarbamimidoyl)benzoate(40069-10-1)
    11. EPA Substance Registry System: ethyl 4-(N'-hydroxycarbamimidoyl)benzoate(40069-10-1)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 40069-10-1(Hazardous Substances Data)

40069-10-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 40069-10-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,0,6 and 9 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 40069-10:
(7*4)+(6*0)+(5*0)+(4*6)+(3*9)+(2*1)+(1*0)=81
81 % 10 = 1
So 40069-10-1 is a valid CAS Registry Number.

40069-10-1Upstream product

40069-10-1Relevant articles and documents

LKB1-AMPK ACTIVATORS FOR THERAPEUTIC USE IN POLYCYSTIC KIDNEY DISEASE

-

Paragraph 086, (2016/06/01)

Compounds are provided for use in treating polycystic kidney disease (PKD) and in associated methods that include a method of modulating (e.g., activating) Liver kinase Bl (LKBI); and a method of modulating (e.g., decreasing activity) mammalian target of

Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores

Trstenjak, Uro?,Ila?, Janez,Kikelj, Danijel

supporting information, p. 302 - 313 (2013/07/27)

Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa an

Design and synthesis of boron containing potential pan-RAR inverse agonists

Das, Bhaskar C.,Tang, Xiang-Ying,Evans, Todd

body text, p. 1316 - 1318 (2012/04/04)

We designed and successfully synthesized the compounds 5 and 8 as potential pan-RAR (retinoic acid receptor) agonists. These two compounds were designed based on an existing pan-RAR agonist (BMS493). We synthesized compound 5, in which the carboxylic acid

Rapid catalyst identification for the synthesis of the pyrimidinone core of HIV integrase inhibitors

Bellomo, Ana,Celebi-Olcum, Nihan,Bu, Xiaodong,Rivera, Nelo,Ruck, Rebecca T.,Welch, Christopher J.,Houk, Kendall N.,Dreher, Spencer D.

supporting information; body text, p. 6912 - 6915 (2012/10/08)

A microscale chemistry improvement engine: A pre-dosed microscale high-throughput experimentation additives platform enables rapid, serendipitous reaction improvement. This platform allowed one chemist to set up 475 experiments and analyze the results using MISER chromatography in a single day, thus resulting in two high-quality catalytic systems for the construction of the title compound 1. Support for a single-electron transfer mechanism was obtained. Copyright

AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

-

Page/Page column 16-17, (2010/04/30)

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1

-

Page/Page column 15, (2010/11/03)

The invention relates to novel thiophene derivatives (1), their preparation and their use as pharmaceutically active compounds.Said compounds particularly act as immunomodulating agents. Formula (I).

AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

-

Page/Page column 41, (2008/12/07)

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 40069-10-1